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Abstract
Second-generation antipsychotics including olanzapine are associated with weight gain, dyslipidemia and
other metabolic disorders. Both animal and clinical studies have shown that co-treatment with betahistine (a
histamine H1 receptor agonist/H3 receptor antagonist) is effective in controlling olanzapine-induced weight
gain. In the present study, we investigate whether co-treatment with betahistine is able to prevent dyslipidemia
induced by chronic olanzapine treatment and the underlying mechanisms. Female rats were orally
administered with olanzapine (1 mg/kg, t.i.d.) for 3.5 consecutive weeks and then a 2.5-week drug
withdrawal. Then, rats were divided into 4 groups for 5 weeks treatment: (1) vehicle, (2) olanzapine-only (1
mg/kg, t.i.d.), (3) betahistine-only (9.6 mg/kg, t.i.d.), and (4) olanzapine and betahistine (O + B) co-
treatment. After completing treatment, hepatic mRNA expression was measured by qRT-PCR, while the
protein levels were detected by western blot. In our study, olanzapine-only treatment significantly increased
triglyceride accumulation and non-esterified fatty acids (NEFA), and upregulated mRNA expression of sterol
regulatory element binding protein 1 (SREBP-1) and its target genes, while these alterations were ameliorated
by O + B co-treatment. Hepatic AMP-activated protein kinase α (AMPKα) was activated in the O + B co-
treatment group, with a significant reduction in nuclear SREBP-1 protein expression but an increased
expression of peroxisome proliferator-activated receptor-α (PPARα) and its-responsive molecule(CPT1A),
compared with olanzapine-only treatment. In addition, olanzapine significantly increased hepatic histamine
H1 receptors, while O + B co-treatment significantly reversed them to normal levels. This study provided the
first evidence that betahistine could act on hepatic H1 receptors via modulation of AMPKα-SREBP-1 and
PPARα-dependent pathways to ameliorate olanzapine-induced dyslipidemia in rats.
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Abstract 19 
Second-generation antipsychotics including olanzapine are associated with weight gain, 20 
dyslipidemia and other metabolic disorders. Both animal and clinical studies have shown that co-21 
treatment with betahistine (a histamine H1 receptor agonist/H3 receptor antagonist) is effective 22 
in controlling olanzapine-induced weight gain. In the presentstudy, we investigate whether co-23 
treatment with betahistine is able to prevent dyslipidemia induced by chronic olanzapine 24 
treatment and the underlying mechanisms. Female rats were orally administered with olanzapine 25 
(1 mg/kg, t.i.d.) for 3.5 consecutive weeks and then a 2.5-week drug withdrawal. Then, rats were 26 
divided into 4 groups for 5 weeks treatment: (1) vehicle, (2) olanzapine-only (1 mg/kg, t.i.d.), (3) 27 
betahistine-only (9.6 mg/kg, t.i.d.), and (4) olanzapine and betahistine (O+B) co-treatment.After 28 
completing treatment, hepatic mRNA expression was measured by qRT-PCR, while the protein 29 
levels were detected by western blot. In our study, olanzapine-only treatment significantly 30 
increased triglyceride accumulation and non-esterified fatty acids (NEFA), and upregulated 31 
mRNA expression of sterol regulatory element binding protein 1 (SREBP-1) and its target genes, 32 
while these alterations were ameliorated by O+B co-treatment. Hepatic AMP-activated protein 33 
kinaseα (AMPKα)was activated in the O+B co-treatment group, with a significant reduction in 34 
nuclear SREBP-1 protein expression but an increased expression of peroxisome proliferator-35 
activated receptor-α (PPARα) and its-responsive molecule(CPT1A), compared with olanzapine-36 
only treatment. In addition, olanzapine significantly increased hepatic histamine H1 receptors, 37 
while O+B co-treatment significantly reversed them to normal levels. This study provided the 38 
first evidence that betahistine could act on hepatic H1 receptors via modulation of AMPKα-39 
SREBP-1 and PPARα-dependent pathways to ameliorate olanzapine-induced dyslipidemia in 40 
rats. 41 
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TG: triglyceride 63 
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1. Introduction 64 
Second-generation antipsychotics (SGAs) including olanzapine and clozapine are commonly 65 
used in clinicsfor controlling schizophrenia symptoms and other psychotic disorders [1-3]. 66 
Overthe lastfew decades, weight gain and other metabolic disorders caused by SGAs have 67 
attractedincreasing attention[4, 5].Dyslipidemia is one of the troublesome side-effects associated 68 
with chronic antipsychotic medication, which may further causecardiovascular disease, stroke, 69 
and premature death[6, 7]. 70 
 71 
Although dyslipidemia could be the consequence of obesity, recent studies demonstratethat 72 
SGAs have direct effects on the liver and/or adipose tissue in inducing dyslipidemia without 73 
weight gain[8-10]. First, the lipogenic transcription factor sterol regulatory element binding 74 
protein 1 (SREBP-1) and target genes are thought to be one of the possible pathways involved in 75 
SGA-induced hepatic lipid dysregulation. We have recently shown thatmRNA expression 76 
ofSREBP-1 and target genes in the liver and fat tissue wasstrongly affected by a single oral 77 
olanzapine administration[11].In addition, SGAs (especially clozapine) exposurein the cultured 78 
cells induces atime-dependent proteolytic cleavage of SREBP-1,in whichmRNA expression of 79 
the cluster of lipidbiosynthesis-related genes is directly up-regulated, without a preceding 80 
elevationof SREBP gene expression[12].These data suggestthat SGA-mediated upregulation of 81 
the SREBP-1-controlled transcription systemand activation of the SREBP-1 cleavage process in 82 
the peripheral tissues may play an important role in the elevation of lipid accumulation. Second, 83 
peroxisome proliferator-activated receptor-α (PPARα) is a critical regulator of fatty acid 84 
oxidation, in which activationof PPARα promotes the expression of genes required for fatty acid 85 
and lipoprotein metabolism in mitochondria, such as carnitine palmitoyltransferase 1 (CPT1) 86 
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[13]. Recently, it has been reported that olanzapinedownregulated transcriptional activity of 87 
PPARαto augment hepatic lipid accumulation in an AMPK-dependent manner in rat primary 88 
hepatocytes[14]. Given the pivotal role of SREBP-1 and PPARα in mediating hepatic 89 
dysregulation of lipid metabolismcaused bySGAs, it is important to identify and characterize 90 
factors as targets for reversing lipid dysfunction. 91 
 92 
AMPK also plays an important role in regulating hepatic lipid metabolism [15]. In short-term 93 
regulation, AMPK phosphorylates and inactivates acetyl CoA carboxylase (ACC) and 3-94 
hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase, thus inhibiting both cholesterol and fatty 95 
acid biosynthesis [16].In addition, phosphorylation by AMPK could also affect PPARα activity 96 
including ligand affinity and DNA binding [17].Olanzapine-induced hepatic dysregulation of 97 
lipid metabolism has been reported to be resulted from reduced PPARα activity by inhibiting 98 
AMPK signalling in hepatocyte [14].In the long-term, AMPK has been reported to regulate 99 
hepatic lipogenic gene expression by inhibiting transcription factors including SREBPsto reduce 100 
the transcription rate[16].However, Schmidt et al. found that olanzapine-induced disturbances in 101 
hepatic lipid metabolism were mediated through activation of AMPK and mammalian target of 102 
rapamycin pathways in female mice [18]. Therefore, further study is necessary to assess the 103 
potential contribution of chronic SGAs on lipid metabolism from hepatic AMPK pathway. 104 
 105 
Although it is not known whether the hepatic histamine receptors are involved in SGA-induced 106 
dyslipidemia, histamine is a classic inflammatory mediator in peripheral tissues and also 107 
functions as a neurotransmitter in the brain [19]. The histaminergic receptors in the 108 
hypothalamus appear to be an important mediator of feeding behaviour and body weight 109 
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regulation [20], which may further regulate obesity and dyslipidemia [21, 22].The high binding 110 
affinity of SGAs to H1R and its modulatingrole in the hypothalamic AMPK pathway have been 111 
evidenced asone key mechanismfor amarked increase in food-intake/weight gain [21-24]. 112 
 113 
Betahistine, a histamine H1R agonist/H3R antagonist, has been successfully used to 114 
prevent/reduce olanzapine-induced weight gain in both rats and schizophrenia patients [21, 25, 115 
26].Recent reportsdemonstrate that co-treatment of olanzapine with betahistine significantly 116 
reduces weight gain and feeding efficiency [25, 27]. In a clinical trial, when co-administered 117 
with olanzapine (10 mg/day) for 6weeks, the mean weight gain in schizophrenia patients with 118 
betahistine/olanzapine co-treatment (3.1 ± 0.9 kg) was lower than those with olanzapine-only 119 
treatment (5.0 ± 1.2 kg)[28].Another short-term clinical trial in first episode schizophrenia 120 
patients showed thatpatients co-treated with olanzapine, betahistine and reboxetine (a selective 121 
norepinephrine reuptake inhibitor)had significantly less weight gain than those treated with 122 
olanzapine only treatment[26]. It is interesting thatbetahistinehas been found to reduce lipid 123 
accumulation in the liver of rats caused by chronic olanzapine treatment[25]. Therefore, it is 124 
important to further investigate the long-term effects ofco-treatment with betahistineon 125 
lipogenesis and lipolysis in the liver and the underlying mechanisms. 126 
 127 
Here, we reported that up-regulated mRNA of SREBP-controlling genes and increased 128 
expression of nuclear SREBP-1 as well as decreased CPT1A protein levels was an underlying 129 
mechanism for dysregulation of hepatic lipid metabolism induced by chronic olanzapine 130 
treatment. An important consideration is long-term prevention and therapy of SGA-induced 131 
dyslipidemia, since schizophrenia patients face life-long and repeated treatment with SGAs. 132 
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Using an animal model with repeated and chronic olanzapine treatment, we further showed 133 
thatchronic co-treatment with betahistinestimulated AMPKα phosphorylation to reduce the 134 
cleavage of p-SREBP-1 and to enhance CPT1A-dependent fatty acid oxidation, possibly through 135 
acting on hepatic histamine H1R. These data provided the first evidence to indicate that 136 
betahistine could act at H1R via the AMPKα-SREBP-1 and PPARα-dependent pathways to 137 
ameliorate olanzapine-induced dyslipidemia in rats. 138 
 139 
2. Materials and methods 140 
2.1 Animal housing and treatment 141 
Forty-eight female Sprague-Dawley (SD) rats (200-220 g) were obtained from the Animal 142 
Resources Centre (Perth, WA, Australia) and housed in individual cages and allowed ad libitum 143 
access to water and a standard laboratory chow diet under environmentally controlled conditions 144 
(22°C, with light cycle from 07:00-19:00 and dark cycle from 19:00-07:00) throughout the 145 
experimental period.After one week of environmental familiarization, rats were trained to self-146 
administer a sweet cookie dough pellet (0.3 g, including 30.9% cornstarch, 30.9% sucrose, 6.3% 147 
gelatine, 15.5% casein, 6.4% fibre, 8.4% minerals and 1.6% vitamins) without drugs for one 148 
week [27, 29]. A chronic and repeated olanzapine treatment rat model was used as described 149 
previously[25]. In brief (Fig.1), for the first 3.5 weeks, 48 rats were divided into two groups: half 150 
of them (n=24) were treated with olanzapine (1 mg/kg, Eli Lilly, Indianapolis, USA, t.i.d.), and 151 
the other half were treated with vehicle. From week 3.5 to week 6, norats received any treatment 152 
during this period (e.g. olanzapine was withdrawn). From week 6 to week 11, the two groups 153 
were divided into 4 subgroups (n=12) for further treatment of 5 weeks: subgroup I was control 154 
(received a sweet cookie dough pellet without drug; C); subgroup II was olanzapine-only (1 155 
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mg/kg, t.i.d.; O), subgroup III was betahistine-only (9.6 mg/kg, t.i.d., Manus Aktteva, India; 156 
B);while subgroup IV was co-treatment of olanzapine and betahistine (O+B). The dosage 157 
translation between species based on body surface area followed an FDA guideline [30, 31]. 1 158 
mg/kg olanzapine and 9.6 mg/kg betahistine is equivalent to ~10 mg olanzapine and ~93mg 159 
betahistine in humans at 60 kg body weight, respectively. In addition, betahistine has 3~4 hours 160 
of plasma half-life in humans with one day of urine excretion [32]. The dose (9.6 mg/kg rat body 161 
weight, t.i.d.) used in this study should be equivalent to the human dose (48 mg) used in clinical 162 
trials [26, 28]. Furthermore, betahistine treatment at the dosage range (8-24mg) can significantly 163 
reduce food intake for 24 hours in rats[33]. Body weight, food intake and water intake were 164 
measured once per week.All experimental procedures have beenapproved by the Animal Ethics 165 
Committee, University ofWollongong, Australia (AE11/10); and complied with theAustralian 166 
Code of Practice for the Care and Use of Animals forScientific Purposes (7th edition, 2004). 167 
 168 
After completing treatment, all rats were sacrificed by carbon dioxide asphyxiation. The liver 169 
was weighed, and then collected and frozen in liquid nitrogen immediately followed by storage 170 
in a -80 ℃ freezer until further analysis. Cardiac blood was collected in EDTA-coated tubes, and 171 
then centrifuged (3000 rpm, 10 min, 4 ℃) to separate the plasma which was stored at -80 ℃ 172 
freezer until assay. 173 
 174 
2.2 Plasma and liver lipid analyses 175 
Plasma was assayed for total cholesterol, triglycerides, low-density lipoproteins-cholesterol 176 
(LDL-C) as well as high-density lipoproteins-cholesterol (HDL-C) by using the Thermo 177 
Scientific Kit on a Konelab 30i biochemistry analyzer (Thermo Fisher Scientific Oy,Vantaa, 178 
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Finland). Non-esterified fatty acid (NEFA) was measured by using NEFA C kit (Wako 179 
Chemicals, Richmond, VA). 180 
 181 
Liver lipids were extracted in Folch solution (chloroform/methanol, 2:1, v/v) [34]. Liver samples 182 
(0.1 g) were homogenized in 2.0 ml Folch solution. Extracts were then washed once with 0.2 183 
volume of 0.9% NaCl solution and twice with methanol/water (1:1, v/v). The organic phase was 184 
separated and brought up to 2.0 ml with chloroform. Fifty microliters of each sample were mixed 185 
with 10 μl of 50% Triton X-114 in chloroform (v/v). Samples were air dried and then subjected 186 
to colorimetric enzymatic assays for total cholesterol or triglycerides (Thermo Scientific)[35].  187 
 188 
2.3 Oil Red O staining and liver histology 189 
For the visualization of hepatic lipid content, cryostat sections were cut at 12 μm, fixed with 10% 190 
formalin for 5 minutes and lipid droplets deposition was detected by Oil-Red-O (ORO) staining 191 
(Sigma-Aldrich 01516, St Louis, MO, USA). Sections were rinsed with 60% isopropanol and 192 
stained for 15 min with filtered ORO solution (0.5% in isopropanol followed by 60% dilution in 193 
distilled water). After two rinses with 60% isopropanol and distilled water, slides were 194 
counterstained with hematoxylin (Sigma-Aldrich GHS232, St Louis, MO, USA) for 15 seconds, 195 
rinsed with water and mounted. For quantitative analyses of ORO staining, images were 196 
randomly sampled using  a Leica DMRB microscope (Leica Systems, Toronto, Ontario, Canada) 197 
across 2 adjacent sections on the same slide (N=6 individual livers) in each treatment group.The 198 
area of positive staining for ORO was calculated as a percentage of total section area, and an 199 
average lipid droplet size was calculated by utilizing morphometry software ImageJ (version 200 
1.46) [36]. 201 
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 202 
2.4 RNA extraction, cDNA synthesis, and gene expression analysis 203 
Total RNA from liver tissue was prepared using a PureLink® RNA Mini Kit (Life 204 
technologiesTM, USA). First strand cDNA was synthesized from 1.4 μg of DNase I(On-Spin 205 
Column DNase, USA)-treated total RNA with random hexamer primers using SuperScript® 206 
VILOTM cDNA synthesis Kit (InvitrogenTM, USA) by incubation at 42 °C for 60 min.Acc1 207 
(Rn00573474_ml),Fasn (Rn01463550_m1), Scd1(Rn00821391_gl), Pparα 208 
(Rn00566193_ml),Cpt1a (Rn00580702_m1) andSrebp-1 (Rn01495769_ml) mRNA 209 
expressionwere determined by qRT-PCR in duplicate using TaqMan® Gene Expression 210 
Assays(Applied Biosystems, Foster City, USA) on LightCycler® 480 (Roche, Penzberg, 211 
Germany). The cycling parameters were 95 °C 10 min followed by 40 cycles (95 °C 15 s, 60 °C 212 
1 min). All gene expression levels were normalized relative to two endogenous control genes, β-213 
Actin (Actb)(Rn00667869_ml) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 214 
(Rn01775763_gl). The 2-ΔΔCT method was used to calculate the results.  215 
 216 
2.5 Preparation of nuclear and cytoplasmic extracts 217 
Nuclear and cytoplasmic extracts were prepared from rat livers using the NE-PER™ nuclear and 218 
cytoplasmic extraction reagent kit (Pierce Biotechnology, USA), according to the manufacturer's 219 
instructions. Protein concentration was detected by SpectraMax Plus 384 absorbance microplate 220 
reader (Molecular Devices, USA)using the Bio-Rad DC™ Assay. Transcription factors including 221 
SREBP-1 (1:1000, Santa Cruz, sc-364), and PPARα (1:1000, Santa Cruz, sc-9000) were detected 222 
with western blot analysis. 223 
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 224 
2.6 Western blot analysis 225 
Whole-protein lysates of liver tissue were extracted using 10% Nonidet P-40 lysis buffer 226 
l(Invitrogen, Camarillo, CA, USA) supplemented with 1% protease inhibitor cocktail (Sigma-227 
Aldrich), 0.5 mM β-Glycerophosphate (Invitrogen) and 1.0 mM phenylmethylsulfonyl fluoride 228 
(Sigma-Aldrich). Protein concentrations were measured with a protein assay reagent using the 229 
Bio-Rad DC™ Assay. Aliquots containing 10 μg of proteins were loaded onto an 8% to 12% 230 
sodium dodecyl sulfate–polyacrylamide gel, transblotted onto polyvinylidene difluoride (PVDF) 231 
membrane (Bio-Rad), blocked with 5% BSA in Tris-buffered saline with 0.1% Tween-20, and 232 
then incubated with the primary antibodies including anti-AMPK(1:2000, CellSignally, #2532), 233 
anti-phospho-AMPK (1:2000, Cell Signally, #2535), anti-histamineH1R (1:1000, Santa Cruz, # 234 
SC-20633), anti-histamineH3R (1:1000, Santa Cruz, # SC-390140),anti-ACC1 (1:1000, Cell 235 
Signaling, #3662), anti-phospho-ACC1 (1:1000, Merck Millipore, 07-303), ATGL (1:2000, 236 
Abcam, ab109251), anti-CPT1A (1:1000, Abcam, ab176320), and anti-β-actin (1:2000, Santa 237 
Cruz, sc-47778). The membrane was then incubated with horseradish peroxidase–conjugated 238 
goat anti-rabbit (1:5000, Millipore) or goat anti-mouse IgG (1:5000, Millipore). The bound 239 
complexes were detected with Amersham Hyperfilm ECL (GE Healthcare, Life Science, USA) 240 
and quantified by a GS-800 image densitometry (Bio-Rad). The ratio to β-Actin was calculated 241 
and presented as fold changes, setting the values of control rats as one. 242 
 243 
2.7 Statistical analysis 244 
All data were analysed using SPSS software (version 21.0, IBM, NY, USA). The Kolmogorov-245 
Smirnov test was used to examine the distribution of data from all experiments. Data were 246 
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analysed by Two-way analysis of variance (ANOVA) (OLANZAPINE × BETAHISTINE), 247 
followed by multiple comparisons using post-hoc Dunnett t-tests. A nonparametric Mann-248 
Whitney U test was performed for data without normal distribution. Pearson’s correlation test 249 
was used to analyse the relationships among the measurements. Statistical significance was 250 
accepted when p<0.05. The results were calculated as the mean ± SEM. 251 
 252 
3. Results 253 
Body weight, adipose mass and energy intake data have been reported previously [25]. Briefly, 254 
olanzapine-only rats displayed a significantly higher body weight gain, white adipose mass 255 
(including inguinal, periovarian, mesentery and perirenal fat), food intake and feeding efficiency, 256 
whereas the O+B co-treatment reversed weight gain, white fat mass, and feeding efficiency 257 
compared with the olanzapine-onlytreatmentgroup. 258 
 259 
3.1Effects onlipid concentration in the liver and blood 260 
As shown in Table 1, plasma TG levels weresignificantly increased (1.06±0.11(C)vs. 261 
1.26±0.13(O) mmol/l, p<0.05), as were plasma NEFA levels (0.28±0.03(C)vs. 0.35±0.03(O) 262 
mEq/l, p<0.05) in olanzapine-only treatment.Although betahistine-only treatment had no effect 263 
on plasma TG and NEFA levels compared to the control,O+B co-treatment significantly reversed 264 
olanzapine-induced plasma TG (p<0.05) and circulating NEFA (p<0.01) levels to near the 265 
control levels. Aslightcorrelation was observed between NEFA levels and TG levels in the 266 
plasma (r=0.298, p=0.077). However, plasma HDL-C, LDL-C, as well as total cholesterol 267 
showed no significant changes in all treatment groups. 268 
 269 
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After chronic treatment with olanzapine, a 14% increase in the liver weight of the control group 270 
was detected(13.76±0.44(O)vs. 12.09±0.26(C) g, p<0.05). Oppositely, O+B co-treatment led to a 271 
significant reduction in liver weight(12.78±0.39(O+B) vs.13.76±0.44(O)g; p<0.05). Similar to 272 
what we observed in plasma, olanzapine-only treatment induced a significant accumulation of 273 
lipids in the hepatic crude extracts (11.2±0.21 mg/g, p<0.01; Table 1) compared with the control 274 
(7.91±0.85 mg/g). Moreover, a positive correlationwas observed between plasma and hepatic 275 
TGlevels(r=0.359, p=0.040).Althoughhepatic cholesterol levels were increased by olanzapine 276 
treatment (0.41±0.13 mmol/g), it was not significant compared with the control rats (p=0.14).  277 
 278 
In addition, olanzapine-only treatment rats significantly increased positive ORO staining 279 
(133.65±6.09% of the control value, p<0.001) for neutral lipids and increased lipid droplet size 280 
(152.39±28.27% of the control value, p<0.01) compared with the control (Fig.2). It should be 281 
noted that there was a significantly lower positive ORO staining in the O+B co-treatment group 282 
than the olanzapine-only group (~31.57% reduction, p<0.01). Although the betahistine-only 283 
group had a lower lipid accumulation than the control, the difference was not significant 284 
(86.97±4.10% of control value, p=0.170).The images counterstained with hematoxylin showed 285 
that there were no notable histological changes in treatment groups compared with the control 286 
(Fig. 2A-2D). 287 
 288 
3.2Effects of olanzapine and/or betahistine treatment on the SREBP-1 pathway 289 
To investigate one of the most important pathways controlling lipid biosynthesis, we quantified 290 
mRNAexpression of genes involved in the SREBP-1 pathway, and examined the protein level of 291 
the mature form of SREBP-1 (m-SREBP-1) in the liver. At the transcription levels, olanzapine-292 
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only treatment led to a significant transcriptional response with upregulation of Srebp-1and its 293 
target lipid-related genes (Acc1, Fasn, Scd1) (p<0.01; Fig. 3A-3D). In particular, Scd-1 had 5.18 294 
± 0.56-fold increase in the olanzapine-only treated group (p<0.01; Fig. 3D). Compared to 295 
olanzapine-only treatment, co-treatment with betahistine exhibited a significant decrease in 296 
mRNA expression of Acc1 (2.36±0.23-fold (O) vs. 1.41±0.01-fold(O+B), p<0.05; Fig. 3B), Fasn 297 
(2.05±0.33-fold(O) vs. 1.49±0.12-fold(O+B),p<0.01; Fig. 3C) and Scd1 (5.31±0.56-fold(O) 298 
vs.1.27±0.23-fold(O+B), p<0.01; Fig.3D). Although it was notsignificant,in O+B co-treatment 299 
rats, mRNA expression of Srebp-1 was ~30% lesscompared to the olanzapine-only group 300 
(p=0.175). At the protein levels, olanzapine significantly increased the abundance of the mature 301 
form of SREBP-1 (m-SREBP-1; p<0.05)as well as the ratio ofm-SREBP-1over precursor 302 
formSREBP-1(p-SREBP-1) protein levels (0.32 (O)vs. 0.22(C), p<0.05; Fig.3F), whereas the p-303 
SREBP-1did not show any significant changes(Fig. 3G). It was important that betahistine-only 304 
and O+B co-treatment led to a significant decrease in m-SREBP-1 protein levelscompared to 305 
olanzapine-only treatment (both p<0.05, Fig. 3E), andthe ratio ofm-SREBP-1 overp-SREBP-1 in 306 
the O+B co-treatment group returned normal levels (Fig. 3F). Furthermore,we also observed a 307 
positive linear relationship between plasma TG concentration and m-SREBP-1 protein levels 308 
(r=0.459, p=0.012) 309 
 310 
3.3 Effects of olanzapine and/or betahistine treatment on the PPARα-dependent pathway 311 
To determine whether betahistine was able to enhancefatty acid β-oxidation to reverse 312 
dyslipidemia induced by olanzapine, we examined mRNA and protein levels of PPARα (a 313 
nuclear receptor) and CPT1A (the rate-limiting enzyme of mitochondrialβ-oxidation). As shown 314 
in Fig. 4A and 4D, both betahistine-only and O+B co-treatmentsignificantlyup-regulatedmRNA 315 
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expression levelsof PPARα(p<0.01),as well as its protein levels,compared to the control 316 
(p<0.05). Furthermore, a negative linear relationship between hepatic triglyceride content and 317 
PPARα protein levels was observed (r=-0.316, p=0.039). Surprisingly, olanzapine-only 318 
treatment did not cause a significant change in PparαmRNA levels but led to a markedincreaseat 319 
PPARα protein levels (p<0.01; Fig. 4A and 4D).On the other hand, both in the betahistine-only 320 
and O+B co-treatment group, mRNA expression of Cpt1a was significantly higher than in the 321 
control rats (bothp<0.05; Fig. 4B).Importantly, olanzapine-only significantly decreased the 322 
protein levels of CPT1A (p<0.05; Fig. 4E), while no significant change in transcription levels 323 
was observed. As another PPARα target gene, ATGL protein expression was not affected by 324 
olanzapine and/or betahistine treatment (Fig. 4F). 325 
 326 
3.4 Effects of olanzapine and/or betahistine treatment on AMPKα phosphorylation 327 
To determine whether AMPKα is involved in olanzapine and/or betahistine-induced 328 
dyslipidemia, the protein levels of AMPKα, phosphorylated AMPKα (pAMPKα, Thr172), and 329 
phosphorylated ACC1 (pACC1, Ser79), a downstream target of AMPKα, were measured. As 330 
shown in Fig. 5A-5C, although the AMPKα levels were not significantly altered in all groups, 331 
the protein levels of pAMPKαand the ratio of pAMPKα/AMPKαdemonstrated that betahistine 332 
efficiently stimulated the phosphorylation of AMPKα at T172 in the liver (p<0.05).However, 333 
olanzapine-only treatment had no effect on pAMPKα levels. Moreover,O+B co-treatment also 334 
caused a ~25%increase in hepaticlevels of pAMPKα compared with the olanzapine-only 335 
treatment (p<0.05; Fig. 5B). Consistent with the observed changes in pAMPKα expression, 336 
phosphorylation in the liver of acetyl-CoA carboxylase 1 (ACC1) (a downstream molecule of 337 
AMPK)wassignificantly elevated at ~54% and ~47% of control value by betahistine-only 338 
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treatment and O+B co-treatment, respectively(both p<0.05; Fig. 5F).By contrast, co-treatment 339 
with betahistine significantly reduced ACC1 protein levels to ~63% of the control value (p<0.05), 340 
while olanzapine-only treatment led toa ~73% increase compared with the control(p<0.01; Fig. 341 
5E). ACC1 protein levels were positively correlated with m-SREBP-1 protein levels (r=0.603, 342 
p=0.004) which was negatively correlated with AMPK phosphorylation in the liver (r=-0.387, p= 343 
0.009). Additionally, a strong positive correlation of protein levels between pAMPKα and 344 
CPT1A was observed (r=0.849, p< 0.001).  345 
 346 
3.5 Effects of olanzapine and/or betahistine treatment on histamine H1 receptor 347 
To test the hypothesis that the effects of olanzapine and/or betahistine on lipid metabolism might 348 
be via action on hepatic histamine receptors to modulate AMPK, we determined the expression 349 
of H1R and H3R. As shown in Fig.5F, the protein levels of H1Rweresignificantly increased 350 
(~67%)by olanzapine-only treatment(p<0.05), and positively correlated with m-SREBP-1 protein 351 
levels (r=0.343, p=0.05). It was interesting that O+B co-treatment significantly reduced the H1R 352 
levels to ~76% (p<0.01; Fig. 5F). We further found a strong negative correlation between H1R 353 
levels and circulating NEFA concentration (r=-0.502, p=0.005) as well as hepatic pAMPK levels 354 
(r=-0.772, p<0.001).However, H3R was not affected by any of these treatments (all p>0.05; Fig. 355 
5G). 356 
 357 
4. Discussion 358 
The present study showed that chronic treatment with olanzapineled to a significant increase in 359 
body weight gain and elevated the circulating NEFA, TG and hepatic lipid accumulation without 360 
altering cholesterol synthesis in rats. Interestingly, co-treatment with betahistine 361 
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improvedolanzapine-induced dyslipidemia. Our data furtherrevealed that olanzapine-only 362 
treatment enhanced the cleavage of 125-kDa p-SREBP-1 and increased transcriptional 363 
expression of the crucial genes involved in lipogenesis, while it reduced CPT1A protein levels 364 
involved in fatty acid β-oxidation. By contrast, as expected, co-treatment with betahistine 365 
reduced lipid accumulation, possiblythrough the following process: 1)inhibited olanzapine-366 
induced transcriptional activation of lipogenesis genes including Srebp-1, Acc1 and Scd1; 2) 367 
increased AMPKα phosphorylation to inhibit the cleavage of p-SREBP-1 and to suppress the 368 
protein levels of ACC1; and 3)stimulated PPARa and CPT1A expression to modulate fatty acid 369 
β-oxidation. Furthermore, H1R was elevated by olanzapine-only, while it was reversed by O+B 370 
co-treatment. The results suggest that amelioration of olanzapine-induced dyslipidemia after 371 
betahistine co-treatment may be attributable not only to alteration of the transcriptional responses 372 
of lipid-metabolic genes but also, at least in part, to activation ofthe AMPK signalling pathway 373 
via action at hepatic H1 receptor. 374 
 375 
Previous studies showed that olanzapine treatment enhanced mRNA expression of SREBP-1 and 376 
downstream target genes involved in lipogenesis[9, 12, 37]. Our findings further confirmed that 377 
under chronic olanzapine treatment, the induction of increased lipid synthesis was associated 378 
with transcriptional up-regulation of Srebp-1 and its-controlling genes such as Acc1，Fasn，and 379 
Scd1 in the liver.However, it was noteworthy that olanzapine-only treatment led to an up-380 
regulation of Srebp-1 mRNA expression but not a significant increase of p-SREBP-1 protein 381 
expression in this study. Olanzapine augmented the abundance of the transcriptionally active (68 382 
kDa) form of SREBP-1 in the nucleus without a significant effect on the 125-kDa precursor form 383 
of SREBP-1 in the cytoplasm, resulting in an increase in the 68/125-kDa protein ratio. 384 
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Interestingly, it is observed in previous studies that post-translational activation of SREBP-1 was 385 
enhanced to regulate lipid metabolism by chronic olanzapine treatment[38-40]. Overall, these 386 
findings suggested that olanzapine might have a stronger effect on modulating the post-387 
translational process of p-SREBP-1 than just elevating its transcription.In the case of co-388 
treatment, O+B had significantly down-regulated olanzapine-induced mRNA expression of 389 
lipogenesis-related genes, althoughbetahistine-only treatment did not affectthese genes. We 390 
further investigated whether the concentration of circulating NEFA was positively correlated 391 
with m-SREBP-1 expression in our experiment. These findings raise the possibility that O+B co-392 
treatment maymodulatethe post-translational process of SREBP-1 to ameliorate olanzapine-393 
inducedlipid accumulation in liver. 394 
 395 
Of note, olanzapine inducedthe greatest increase in Scd1mRNA expression involved in SREBP-396 
controlling lipogenic genes (a greater than 5-fold up-regulation).Although SCD1 is just a 397 
desaturase that catalyse the synthesis of monounsaturated fatty acids, previous studies have 398 
shown that the elevated SCD1 activity is implicated in a wide range of disorders, including 399 
obesity[41, 42] and hepatic insulin resistance[43]. Moreover, evidence for up-regulation of Scd1 400 
mRNA expression had been obtained in cultured human and rat cell lines following exposure to 401 
SGAstreatment[44, 45], as well as in blood cells of patients treated with 402 
olanzapine[46].Therefore, increased lipid accumulation caused by olanzapine was particularly 403 
likely due to the promotion of Scd1 mRNA expression. By contrast, co-treatment with 404 
betahistine reversed olanzapine-inducedup-regulation ofScd1 mRNA expression.Interestingly, 405 
metformin (a classic approach to treat the metabolic syndrome)also suppressed SCD1 gene 406 
expression through activation of AMPK[47]. Taken together, SCD1 may act as an important 407 
 Page 20  
modulator controlling the development of obesity and dyslipidemia induced by olanzapine and 408 
may be targeted by betahistine co-treatment. 409 
 410 
As an activator of mitochondrial and peroxisomal fatty acid β-oxidation, both betahistine-only 411 
and O+B co-treatment obviously improved the transcriptional response as well as protein levels 412 
of PPARα compared with the control, with a negative correlation between hepatic triglyceride 413 
content and PPARα protein levels. Moreover, co-treatment with betahistine also significantly 414 
induced CPT1A(a PPARα-target moleculeexpression, contributing to an enhancement of β-415 
oxidation. Thus, co-treatment with betahistine might enhance lipolysis to reduce accumulation of 416 
hepatic TG via activation of PPARα.Although there was a significantly up-regulated expression 417 
of PPARα and CPT1A by betahistine-only treatment, hepatic lipid droplets had only a slight (and 418 
non-significant; p=0.17) decrease compared with the control in lipid accumulation. It is worthy 419 
to note that there are over 800 genes, including Srebp-1 and Hsl(Hormone-sensitive lipase), 420 
involved in the lipid droplets accumulation [48, 49]. Therefore, betahistine-induced increase in 421 
the expression of PPARα and CPT1A mayonly partially affect the assembly of lipid droplets.In 422 
the olanzapine-only group, we investigated a significant decrease in CPT1A protein levels, 423 
suggesting that olanzapine-induced dyslipidemia could also be relevant for antilipolytic effects 424 
related to fatty acid β-oxidation. However, unexpectedly, there was no significant difference of 425 
PPARαmRNA levelsbetweenthe olanzapine-only and control groups, but a marked increase inits 426 
protein expression in the olanzapine-only group. It should be noted that clozapine treatment 427 
caused the hepatic transcriptional response of Pparαwith an initial up-regulation at 1~3 h and a 428 
subsequent down-regulation at 6 h after drug exposure [50], whilein HepG2 cells rather than 429 
primary hepatocytes of clozapine-fed mice, olanzapine decreased transcriptional activity of 430 
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PPARα in an AMPK-dependent manner [14].Therefore, it is possible that the regulation 431 
ofPPARαexpression is not only a direct stimulation of SGAs but also a feedback-response to 432 
significantly increased fatty acid levels as well as multiple changes of hormone[51] 433 
duringchronic olanzapine treatment. 434 
 435 
In this study, elevated H1R levels were observed in the liver,while O+B co-treatment 436 
significantly down-regulated H1R expressionand induced an increase in the pAMPKα as well as 437 
pACC1 (downstream molecule of AMPK).It was worth noting that an inverse correlation was 438 
foundpreviously between AMPK and SREBP-1 activities in hepatocytes and in mice livers[52, 439 
53].Consistent with previous reports, there was a negative correlation between hepatic m-440 
SREBP-1 protein levels and pAMPKα levels in this study.With an increase in pAMPK levels, 441 
betahistine-only treatmentled toa significant inhibition of the transcription levels of Acc1, 442 
whileO+B co-treatment down-regulatedolanzapine-induced mRNA expression of SREBP-443 
controlled lipogenic genes. Although the physiological significance of the phosphorylation of 444 
AMPKα by betahistine is far from understood, these findings support the idea that the effects of 445 
betahistineon fatty acid synthesis are at least partially due to AMPKα-mediated regulation of 446 
SREBP-1 activity via hepatic H1R (Fig. 6).As a potent histamine H1 antagonist, olanzapine-only 447 
treatment showed an up-regulation of Srebp-1 and its-controlling genes, as well as an increase of 448 
the post-translational process of SREBP-1, while co-treatment with betahistine (as a H1 agonist) 449 
downregulated olanzapine-induced mRNA expression of lipogenesis-related genes. Therefore, it 450 
is possible that betahistine, via H1 receptors, could activate phospholipase C (PLC), with a 451 
subsequent increase in cytosolic Ca2+ concentration and activation of AMPK through CAMKKβ 452 
(Ca2+ calmodulin-dependent protein kinase kinase β) [54]. Lauressergues et al. have found that 453 
 Page 22  
the transcriptional inductions (Fasn, Scd1, HmgCoAr, Ldlr mRNA) promoted by clozapine could 454 
be completely reversed when BAPTA-AM (Selective Ca2+ chelator) was co-incubated with 455 
clozapine in the Immortalized Human Hepatocyte cell model, showing that calcium chelation 456 
may prevent SREBP-1, SREBP-2 gene expression induced by clozapine [44]. Therefore, it is 457 
important in further studies to investigate the effects of betahistin/olanzapine co-treatment on 458 
PLC expression and Ca2+ concentration in the liver.In addition to the effects on the H1R levels, 459 
histidine decarboxylase (HDC) could be affected by olanzapine and/or betahistine treatment, 460 
which may further cause changes in histamine synthesis. Therefore, it is important in further 461 
study to analyse the alteration of the HDC protein levels and histamine content. Furthermore, 462 
the“pleiotropic effects” of hetahistinemight be involved in improving lipogenesis. Since 463 
betahistine is also a H3R antagonist, it might modulate SREBP-1 expression through H3 464 
receptors. However, this study did not find any effects on H3 receptors by either olanzapine or 465 
O+B co-treatment, which may suggest a key role of histamine H1 receptors on the regulation of 466 
betahistine.In fact, it is also worth to note that the antibody used in this study targets at an 467 
epitope mapping between amino acids 301-405 near the C-terminus of H3R[55].Due to a large 468 
variety of H3R isoforms in the protein sequences existed between different tissues[56, 57],the 469 
limitation of the antibody used in this study may not allow us to detect the possible changes in 470 
other H3R isoforms.Therefore, we could not completely exclude the role of histamine H3R in 471 
betahistin’s effects, in which betahistine may act on H3R to activate other effector pathways, 472 
including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) 473 
pathways [58, 59]. Taken together,other specific antibodies could be used in further studies to 474 
investigate whether betahistine has any effect on other isoforms of H3R in the liver. 475 
 476 
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On the other hand, it should also be noted that pAMPKα levelspositively correlated with 477 
CPT1Aprotein levels.Cpt1a is a PPARα-responsive gene, and that induction of PPARa in human 478 
hepatocytes increases CPT1A mRNA levels[60]. Therefore,betahistine-induced activation of 479 
AMPKαmay1)decrease the activation of p-SREBP-1; 2) lead to the phosphorylation at Ser-79and 480 
inhibition of ACC1[61]. This inhibition may result in a drop in the level of malonyl-CoA which 481 
itself is an inhibitor of CPT1A [16]. With a drop in the inhibition of CPT1A, β-oxidation of fatty 482 
acid within the mitochondria will be increased [62]; or 3) increase PPARα levels to promote 483 
CPT1A expression, enhancing fatty acid oxidation.  484 
 485 
The female rats were used in this study, because the SGA-induced weight gain model has been 486 
consistently established and validated in female rats in our and other laboratories [27, 63-65], 487 
while it could not be consistently modelled in male rodents [66]. Clinically, it is also a common 488 
observation that female patients have a much higher risk than males for SGA-induced weight 489 
gain and other metabolic side-effects [67-70]. Previous studies have shown that betahistine could 490 
reduce olanzapine-induced weight gain in both male and female schizophrenia patients [26], as 491 
well as in female rats [27]. Betahistine is also effective to inhibit food intake in male rats [33]. 492 
Therefore, it is most likely that betahistine co-treatment is also effective to ameliorate 493 




This study provided further evidence that chronic olanzapine induces accumulation of hepatic 498 
lipid. More importantly,co-treatment with betahistine appears to be effective inameliorating 499 
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olanzapine-induced dyslipidemia through modulation of the AMPKα-SREBP-1and PPARα-500 
dependent pathways(Fig. 6). A great deal of further work needs to be carried out to delineate not 501 
only the precise molecular mechanisms by which betahistine activates AMPKα to regulate 502 
lipolysis, but also the signalling pathways that link hepatic H1R with AMPKα. Furthermore, 503 
clinicaltrials have shown that short-term betahistine co-treatment produces a clinically significant 504 
weight-attenuatingeffectin schizophrenia patients treated with olanzapine [26, 28]. Therefore, 505 
further studies are important to identify whether betahistine is also effective to control 506 
dyslipidemia caused by olanzapine and other SGAs in patients.  507 
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FigureLegends 724 
 725 
Figure 1 Outline of the experimental design. 726 
 727 
Figure2O+B co-treatment reduced liver fat accumulation induced by olanzapine. Representative 728 
images of randomly selected sections of liver stained for ORO in rats treated with drugs. 729 
A-D: Representative images counterstained with hematoxylin; E-H: (ORO)-stained 730 
histological sections of livers of rats treated with Vehicle (E), Olanzapine-only (F), 731 
Betahistine-only (G), and O+B co-treatment (H). Intense red color indicates the presence 732 
of neutral lipids, mainly triacyglycerols. Scale bars,100 μm. Inset images were magnified 733 
eight times in order to highlight the lipid-staining morphology. (I) Lipid level of liver. The 734 
data from ORO staining are shown as mean ± SEM.O+B:olanzapine and betahistine co-735 
treatment; ORO: Oil-Red-O. ***, p <0.001; **, p<0.01 vs. control group. #, p<0.05; ##, p 736 
<0.01 vs.olanzapine-only group. 737 
 738 
Figure3Olanzapine stimulated the hepatic lipogenesis related SREBP-1 pathway. (A) Srebp-1, 739 
(B)Acc1, (C) Fasn, and (D) Scd1 mRNA expression shown relative to untreated controls; 740 
(E) The mature form of hepatic SREBP-1 protein levels shown relative to untreated 741 
controls; (F) the ratio ofm-SREBP-1over p-SREBP-1protein levels; (G) Representative 742 
western-blotting images. m-SREBP-1 and p-SREBP-1 denote the mature, nuclear (~68 743 
kDa) and the precursor (~125 kDa) forms of SREBP-1. Data represent mean ± SEM (n=6 744 
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per group). O+B: olanzapine and betahistine co-treatment. *, p <0.05; **, p <0.01 vs. 745 
control group. #, p <0.05; ##, p <0.01 vs.olanzapine-only group. 746 
 747 
Figure 4 Effects of chronic olanzapine and/or betahistine treatment on thePPARα-dependent 748 
pathway. (A) Pparα and (B) Cpt1a mRNA expression shown relative to untreated 749 
controls; (C) Representative western-blotting images; Protein levels of (D) PPARα, (E) 750 
CPT1A, and (F) ATGL shown relative to untreated controls. Data represent mean ± 751 
SEM (n=6 per group).  *, p <0.05; **, p <0.01 vs. control group. #, p <0.05; ##, p 752 
<0.01 vs.olanzapine-only group. 753 
 754 
 755 
Figure 5 Impact of olanzapine and/or betahistine treatment on the AMPK signalling pathway in 756 
the liver.  Protein levels of (A) AMPKα, (B) pAMPKα, (C) the ratio of pAMPKα/ 757 
AMPKα protein levels, (D) ACC1， (E) pACC1 (F) H1R and (G) H3R shown relative 758 
to untreated controls; (H) Representative western-blotting images. Data represent mean 759 
± SEM (n=6 per group). *, p <0.05; **, p <0.01 vs. control group. #, p <0.05; ##, p 760 
<0.01 vs.olanzapine-only group. 761 
 762 
Figure 6 A schematic diagram of the proposed mechanisms for olanzapine-induced dyslipdimia 763 
and preventing effects of betahistine co-treatment. The solid arrow displays two proposed 764 
pathways causing hepatic metabolic disorder of lipid induced by chronic olanzapine 765 
treatment: Ⅰ olanzapine may directly up-regulate the expression of Srebp-1 and its target 766 
genes involved in lipogenesis, and down-regulate the expression of Cpt1a involved in fatty 767 
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acid β-oxidation; and Ⅱ  olanzapine may elevate the cleavage of p-SREBP-1 through 768 
acting at H1R. The dotted arrow displays possible pathways underlying betahistine-769 
mediated improvement of hepatic dyslipidemia: betahistine-induced activation of AMPKα 770 
may ① decrease the activation of p-SREBP-1;  lead to the phosphorylation of ACC1, 771 
with a drop in the inhibition of CPT1A, and therefore increasing β-oxidation of fatty acid; 772 
or  increase PPARα levels to promote CPT1A expression, enhancing fatty acid oxidation. 773 
Betahistine co-treatment appears to be effective in ameliorating olanzapine-induced 774 
dyslipidemia through modulation of the AMPKα-SREBP-1 and PPARα-dependent 775 
pathways. 776 
777 
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Plasma Cholesterol (total), mmol/l 1.87±0.08 2.14±0.12 1.98±0.06 1.94±0.15 
Triglycerides, mmol/l  1.06±0.11 1.26±0.13* 0.85±0.11 1.05±0.08# 
HDL, mmol/l 1.00±0.04 0.95±0.09 1.13±0.06 1.02±0.04 
LDL, mmol/l 0.20±0.02 0.23±0.03 0.22±0.01 0.18±0.01 
NEFA, mEq/l 0.28±0.03 0.35±0.03* 0.22±0.03 0.24±0.02## 
Liver Cholesterol (total), mmol/g 0.32±0.05 0.41±0.13 0.28±0.03 0.33±0.03 
Triglycerides, mg/g  7.91±0.85 11.20±1.01** 7.58±0.827 9.27±0.918# 
 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; NEFA, non-esterified fatty acids. 
 Page 40  
Hepatic lipids were extracted from control, olanzapine-treated, betahistine-treated, and O+B co-
treatment rats and measured against known standards. Data are representative of independent 
measurements for each parameter (n=12). *, p<0.05; **, p<0.01 vs. control group. #, p <0.05; ##, 
p<0.01 vs. olanzapine-only group. 
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